An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histologic or cytological confirmation of a malignancy that is advanced (metastatic
and/or unresectable) with measureable disease per RECIST v1.1

- Participants must have received and then progressed or been intolerant to at least 1
standard treatment regimen in the advanced or metastatic setting if such a therapy
exists

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

- Ability to swallow tablets

- Adequate bone marrow and organ function, as defined by the protocol

Exclusion Criteria:

- Participants with known or suspected CNS metastases, untreated CNS metastases, or with
the CNS as the only site of disease (patients with controlled brain metastasis allowed
to enroll)

- Ocular melanoma

- Any significant acute or chronic medical illness

- Prior malignancy

- Other active malignancy requiring concurrent intervention

- Prior organ allograft or allogeneic bone marrow transplantation

- Participants with active, known, or suspected autoimmune disease

- Requirement for daily supplemental oxygen

- Uncontrolled or significant cardiovascular disease

- Pre-existing liver disease

- Gastrointestinal disease known to interfere with absorption

Other protocol defined inclusion/exclusion criteria could apply